 was approximately 00 units. The majority of patients (00% overall, 00% treated with pioglitazone hydrochloride 00 mg, and 00% treated with pioglitazone hydrochloride 00 mg) had no change in their daily insulin dose from baseline to the final study visit. The mean change from baseline in daily dose of insulin (including patients with no insulin dose modifications) was -0 units in the patients treated with pioglitazone hydrochloride 00 mg